The ACT-Accelerator welcomes the commitments made at the Global Health Summit and will work with countries to operationalize rapidly these pledges, both financial and – crucially – for over 100 million doses of scarce vaccine. Current financial commitments are reflected in the ACT-Accelerator interactive funding tracker. However, a significant funding gap remains.
Speeding up an end to the pandemic through the ACT-Accelerator would cost less than 1% of what governments are spending on stimulus packages to treat the consequences of the pandemic. As the economic and social costs of the pandemic continue to escalate, the case for global solidarity, grows even stronger. The world now needs the G20 to ACT.
The Rome Declaration, released at the end of the Summit, reaffirmed leaders’ support for the ACT-Accelerator and underlined the necessity to share the financial burden and close the funding gap, in order for the ACT Accelerator to fulfil its mandate for the equitable allocation and delivery of tests, treatments and vaccines to defeat the pandemic. Of vital importance, the group also emphasized its support for global sharing of vaccine doses approved for emergency use by the World Health Organization (WHO) and through COVAX.
Carl Bildt, Special Envoy for the ACT-Accelerator and former Prime Minister of Sweden, said: “Today’s commitments are welcome – but more action is needed now, not in weeks or months, to change the course of the pandemic. While some countries have moved beyond just words, by donating vaccines and pledging to fully finance the ACT-Accelerator, further action is needed from G20 and G7 leaders if we are to stop this virus from spreading and mutating further. We all have substantial work ahead of us.”
Dr Tedros Adhanom Ghebreyesus, Director General of WHO, said: “We now have an opportunity to fix the global imbalance. First, we need to close the 18.5 billion US dollar funding gap for the ACT Accelerator. Second, we need countries to donate tens of millions of doses of vaccines immediately through COVAX – which is the agreed global mechanism for distributing vaccines. We welcome the generous announcements made today; in the coming weeks and months, we will need hundreds of millions more doses. We need companies to help make donations happen fast, and to give COVAX the first right of refusal on all uncommitted doses now, in 2021. Third, we must urgently and dramatically scale up production of all of these tools, through voluntary licensing, sharing technology and know-how, and waiving intellectual property rights. We are at a critical juncture. The creation of the ACT Accelerator represents a historic, forward-thinking effort based on the principles of solidarity and equity. Let’s seize the moment and finish the job we started.”
- Today’s commitments come at a critical point in the pandemic. Only through concerted and rigorous testing to control virus spread, access to life-saving oxygen and dexamethasone to save lives, and vaccines to protect people – can bring this pandemic under control. A massive disparity in access to tests, treatments and vaccines between the world’s richest and poorest countries is prolonging the pandemic in all parts of the world. Funding the work of the ACT-Accelerator now would speed up an end to the pandemic everywhere.
- Testing rates in high-income countries are 100x the rates in low-income countries, contributing to unmonitored and uncontrolled spread of the virus. Fully funding the work of the ACT-A Diagnostics Pillar would significantly increase testing in low- and middle-income countries and build sequencing capacity to ensure newly emerging virus variants can be quickly identified and managed.
- High-income countries have administered nearly 100x more vaccine doses per inhabitant than low-income countries, leaving millions of healthcare workers and vulnerable populations unprotected in the world’s poorest countries. Fully funding the Gavi COVAX Advance Market Commitment (AMC) and sharing vaccines through ACT-A’s COVAX Facility would protect 27% of the populations in the AMC92 countries by the end of 2021.
- The drastic undersupply of oxygen is risking millions of lives across the world. Fully funding the work of the ACT-A Therapeutics Pillar would save up to 4 million lives with the delivery of life-saving oxygen to those that need it most, and fund research into new treatments to fight the disease.
- Health systems are in many countries unprepared for the roll out of COVID-19 tools, and health workers in low- and middle-income countries are frequently unprotected due to lack of PPE. Fully funding the Health Systems Connector would protect 2 million healthcare workers on the frontlines in LICs with supplies of PPE and help prepare health systems for the roll out of tools to fight COVID-19.
Global solidarity against COVID-19 isn’t just the right thing to do. It’s the fastest and most effective way to defeat the pandemic and get all our lives and economies back to normal.
Notes to Editors
The Access to COVID-19 Tools (ACT) Accelerator is the proven, up-and-running global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020.
The ACT-Accelerator is not a decision-making body or a new organization but works to speed up collaborative efforts among existing organizations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organizations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.
The ACT-Accelerator comprises four pillars: diagnostics, therapeutics, vaccines and health system strengthening.
- The diagnostics pillar, co-convened by the Global Fund and FIND, is focused on ensuring equitable access to new and existing tests, supporting country uptake and deployment and strengthening the diagnostic portfolio with R&D investments in low-cost, easy-to-use and quality tests. In 2021, it is focused on procuring and distributing at least 900 million molecular and antigen rapid tests to low- and middle-income countries.
- The therapeutics pillar is led by Unitaid and Wellcome. Therapeutics can play a role in all stages of COVID-19 disease: to prevent infection; suppress symptoms and spread of infection to others; treat or prevent symptoms; as a life-saving treatment for severe symptoms; and as a treatment that can speed up recovery. The aim in the next 12 months is to develop, manufacture and distribute millions of treatment doses, helping COVID-19 sufferers to recover from the disease.
- The vaccines pillar, convened by CEPI, Gavi and WHO, is speeding up the search for an effective vaccine for all countries. At the same time, it is supporting the building of manufacturing capabilities, and buying supply, ahead of time so that at least 2 billion doses can be fairly distributed to the most high risk and highly exposed populations globally by the end of 2021.
- The health systems connector pillar, led by the World Bank, the Global Fund and WHO, is working to ensure that these tools can reach the people who need them.
- Cross-cutting all of these is the workstream on Access & Allocation, led by WHO.
Since April 2020, the ACT-Accelerator has supported the fastest, most coordinated, and successful global effort in history to develop and rollout tools to fight a new disease. With significant advances in research and development by academia, private sector and government initiatives, the ACT-Accelerator has advanced our understanding of what works to fight the disease. It has transformed our ability to tackle COVID-19 on a global scale: vaccines are being rolled-out worldwide, low-cost high-performing antigen rapid diagnostic tests can now detect transmission anywhere, affordable therapies for severe disease can save lives in any setting, and health systems are being strengthened to help roll out these tools.